AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
